Introduction to Targeted Therapies: CAR T-cell Therapy

Petauri PACT Executive Briefings - 3-Minute Market Insights

Content provided by The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

9M ago 3:30

MP3•Episode home

Send us a text

Introduction to Targeted Therapies: CAR T-cell Therapy
T-cell Transfer Therapy is a special type of immunotherapy that takes a person’s own T-cells (a type of immune cell), adds specific antigens to the T-cells that can identify the cancer cells, and puts them back into the person’s body. Cancer cells express unique antigens (signaling proteins). T-cells are programmed in the lab to find those signals and deliver a cancer stopping treatment right to the individual cancer cell. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (TIL) and CAR T-cell Therapy.
Targeted therapies are evolving rapidly and are increasingly more patient specific, as well as significantly more complex to manufacture and deliver. With any of these therapies, life science companies may need to thoughtfully consider strategies for addressing market access needs, patient journey issues, and the complexities of clinical care delivery protocols.

Need more information? Please email us at [email protected]
Check out @The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics.

https://tkgpact.com/executive-briefings/

63 episodes

#Fitness #Medicine #The Kinetix Group #Healthcare #Pharma #Voice #Triple Aim #Biotech #Health Management #Science #Alternative Health #Biology #Insight